Compare SNT & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNT | SER |
|---|---|---|
| Founded | 1965 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.6M | 56.4M |
| IPO Year | 2023 | 2024 |
| Metric | SNT | SER |
|---|---|---|
| Price | $1.61 | $2.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 11.2K | ★ 49.0K |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $130,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.22 | ★ N/A |
| Revenue Growth | N/A | ★ 132.14 |
| 52 Week Low | $1.43 | $1.22 |
| 52 Week High | $5.34 | $5.83 |
| Indicator | SNT | SER |
|---|---|---|
| Relative Strength Index (RSI) | 34.30 | 45.56 |
| Support Level | N/A | $1.69 |
| Resistance Level | $1.89 | $2.90 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 13.24 | 38.46 |
Senstar Technologies Corp is an international provider of comprehensive physical, video, and access control security products and solutions. The company offers comprehensive solutions for critical sites, which leverage its broad portfolio of homegrown PIDS (Perimeter Intrusion Detection Systems), advanced VMS and SMS (Video Management Software and Security Management Software) with native IVA (Intelligent Video Analytics) security solutions, as well as access control products and technologies. Geographically, the company operates in North America, which derives maximum revenue; Europe; APAC; South and Latin America; and Others.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.